| 1 | the fusogenix plv platform | | | | | | | 4 | 0.44% |
| 2 | antibodies against infectious diseases | | | | | | | 3 | 0.33% |
| 3 | to prevent and treat | | | | | | | 3 | 0.33% |
| 4 | aegis life inc is | | | | | | | 3 | 0.33% |
| 5 | using the fusogenix plv | | | | | | | 2 | 0.22% |
| 6 | notice javascript is required | | | | | | | 2 | 0.22% |
| 7 | javascript is required for | | | | | | | 2 | 0.22% |
| 8 | is required for this | | | | | | | 2 | 0.22% |
| 9 | required for this content | | | | | | | 2 | 0.22% |
| 10 | june 9 2023 aegis | | | | | | | 2 | 0.22% |
| 11 | 9 2023 aegis life | | | | | | | 2 | 0.22% |
| 12 | 2023 aegis life awarded | | | | | | | 2 | 0.22% |
| 13 | aegis life awarded grant | | | | | | | 2 | 0.22% |
| 14 | life awarded grant to | | | | | | | 2 | 0.22% |
| 15 | awarded grant to develop | | | | | | | 2 | 0.22% |
| 16 | grant to develop dnaencoded | | | | | | | 2 | 0.22% |
| 17 | and treat infectious diseases | | | | | | | 2 | 0.22% |
| 18 | is developing vaccines and | | | | | | | 1 | 0.11% |
| 19 | protecting and treating humans | | | | | | | 1 | 0.11% |
| 20 | work together to accelerate | | | | | | | 1 | 0.11% |
| 21 | pharmaceuticals work together to | | | | | | | 1 | 0.11% |
| 22 | entos pharmaceuticals work together | | | | | | | 1 | 0.11% |
| 23 | vaccine strategysigns license agreement | | | | | | | 1 | 0.11% |
| 24 | and entos pharmaceuticals work | | | | | | | 1 | 0.11% |
| 25 | strategysigns license agreement with | | | | | | | 1 | 0.11% |
| 26 | license agreement with ntc | | | | | | | 1 | 0.11% |
| 27 | treating humans from infectious | | | | | | | 1 | 0.11% |
| 28 | and treating humans from | | | | | | | 1 | 0.11% |
| 29 | cytiva and entos pharmaceuticals | | | | | | | 1 | 0.11% |
| 30 | therapeutics aimed at protecting | | | | | | | 1 | 0.11% |
| 31 | at protecting and treating | | | | | | | 1 | 0.11% |
| 32 | with our fusogenix plv | | | | | | | 1 | 0.11% |
| 33 | our fusogenix plv platform | | | | | | | 1 | 0.11% |
| 34 | fusogenix plv platform aegis | | | | | | | 1 | 0.11% |
| 35 | plv platform aegis life | | | | | | | 1 | 0.11% |
| 36 | platform aegis life is | | | | | | | 1 | 0.11% |
| 37 | aegis life is developing | | | | | | | 1 | 0.11% |
| 38 | aegis life’s pipeline includes | | | | | | | 1 | 0.11% |
| 39 | life is developing vaccines | | | | | | | 1 | 0.11% |
| 40 | aimed at protecting and | | | | | | | 1 | 0.11% |